6533b856fe1ef96bd12b329a

RESEARCH PRODUCT

Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older.

Patrick ManckoundiaClémentine RosayJérémie VovelleAlain PutotJérémy BarbenArthur HacquinCamille Baudin-senegasDidier MenuGilles NuemiValentine Nuss

subject

medicine.medical_specialtyVitamin KDigoxinmedicine.drug_classHealth Toxicology and MutagenesisAdministration Oral030204 cardiovascular system & hematologyVitamin kdirect oral anticoagulantsArticle03 medical and health sciences0302 clinical medicineInternal medicineAtrial FibrillationMedicineHumans030212 general & internal medicineMedical prescriptionAgedAged 80 and overbusiness.industryAnticoagulantanticoagulantPublic Health Environmental and Occupational HealthRFurosemideAnticoagulantsAtrial fibrillationVenous Thromboembolismmedicine.diseaseaged 80 and overvitamin K antagonistsCross-Sectional StudiesHeart failureAmbulatoryMedicineFemalebusinessmedicine.drug

description

The effectiveness of direct oral anticoagulants (DOAC) is non-inferior to vitamin K antagonists (VKA) to treat atrial fibrillation and venous thromboembolism (VTE). In this cross-sectional study, we compared older persons taking DOACs to those taking VKAs. We included ambulatory individuals ≥80 years, affiliated to Mutualité Sociale Agricole of Burgundy, who were refunded for a medical prescription in September 2017. The demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs were compared in the DOAC group and VKA group. Of the 3190 included individuals, 1279 (40%) were prescribed DOACs and 1911 (60%) VKAs. Individuals taking VKAs were older than those taking DOACs (87.11 vs. 86.35 years). In the DOAC group, there were more women (51.92% vs. 48.25%) (p = 0.043), less RCD (89.60% vs. 92.73%) (p = 0.002), less VTE (1.80% vs. 6.59%), less severe heart failure (58.09% vs. 67.87%), less severe hypertension (18.22% vs. 23.60%), less severe kidney diseases (1.49% vs. 3.82%), and fewer drugs per prescription (6.15 vs. 6.66) (p &lt

10.3390/ijerph18094443https://pubmed.ncbi.nlm.nih.gov/33922331